Full Press Release Details
we are about to begin 2010, I would like to take the opportunity to look back on
the past year and note the progress that Oramed has made, and look at what is
expected in the near future. Last year, beyond the actual clinical trials,
Oramed was chosen to present at a number of significant scientific conferences,
widening our exposure to the greater scientific community. Also,
Oramed received a substantial grant from the Israeli Office of the Chief
Scientist. In August 2009, Frost & Sullivan awarded Oramed with the
2009 European Oral Drug Delivery Technology Innovation Award. All in all
this has been a very productive and exciting year for Oramed and we are hoping
to move Oramed to the next level in 2010.
beginning of 2010, Oramed has significant milestones; which, if met
successfully, will lead Oramed to new heights and take us a step closer to
changing the paradigm for the treatment of Diabetes:
Results of Phase 2b clinical trials
of Oramed's oral insulin capsule, being conducted in South
at the end of the first quarter of 2010. These trials mark one of
the most important milestones to date for the drug, testing ORMD-0801 for the
first time on a large group of volunteers for an extended duration.
Results are expected during the first
quarter of 2010 from the first-in-human clinical study of ORMD-0901, an oral
submission for FDA approved Phase 2 clinical trials is expected in mid
public side, after keeping a relatively low profile, Oramed has recently engaged
a new investor relations firm, Emerging Markets Consulting LLC (www.emergingmarketsllc.com
in order to enlarge the current investors cadre and expose Oramed to more
investors. EMC will start providing its services to Oramed in early January
2010. Oramed is also considering hiring a new public relations firm
to help expose the Oramed story to a broader audience.
of the entire Oramed team I wish you all a happy and successful